By Timothy S. Donahue
Top Takeaways:
Regulatory pause: The FDA is postponing fast-track approvals for nicotine pouches due to concerns about youth risk.
Market stakes: Pouches continue to be the fastest-growing part of a $22 billion U.S. nicotine market.
Industry impact: Major companies like PMI and BAT face uncertainty despite high demand.
The fastest-growing nicotine category just faced a regulatory setback.
The U.S. Food and Drug Administration is delaying approvals for several nicotine pouch products under its highly watched fast-track review program, signaling a more cautious approach as the category continues to expand. The FDA’s reasoning is one of its oldest: the potential for youth use of next-generation tobacco products, three sources told Reuters.
Regulators are considering evidence that pouches could assist smokers in switching away from combustible cigarettes, while also addressing concerns about youth initiation and new-user addiction, especially among non-smokers. That balancing act is now slowing down decisions.
Tobacco stocks declined on Tuesday morning, led by Philip Morris International, which dropped about 6% at the open after the news broke that the regulatory agency was slowing its review of next-generation nicotine pouch products.
Applications from leading tobacco companies, including Philip Morris International’s ZYN and British American Tobacco’s VELO, are still under review, even though the FDA previously approved a limited number of products, such as Altria’s on! PLUS, under the pilot program.
The delay comes at a critical moment for the nicotine industry. Nicotine pouches are the fastest-growing product segment in the U.S., with millions of users and rapid volume growth. PMI alone sold hundreds of millions of cans of ZYN in 2025, underscoring the category’s scale and momentum.
But growth is now clashing with regulatory caution.
The FDA has clarified that authorization depends on proving a net public health benefit, meaning products must both assist current smokers in switching and prevent an increase in youth initiation. That standard is becoming more difficult to meet than initially expected.
Sources familiar with the process say some applications are effectively in a “holding pattern,” as regulators examine data on youth usage trends and marketing practices. For the industry, the implications are immediate.
Delayed approvals hinder the launch of new or updated products, while older versions stay on the market. At the same time, the slow process increases the risk of extended presence of unauthorized products, a common issue throughout the U.S. nicotine industry. It also increases pressure on a category that has become key to tobacco companies’ long-term strategies.
